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EDITORIALOn neuraminidase inhibitors and evidence-based medicineM. Paul1 and L. Leibovici2
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Tel-Aviv University, Tel-Aviv, IsraelAbstractThe quest initiated by the Cochrane authors to obtain the best available evidence on the efﬁcacy of neuraminidase inhibitors is nearing
completion, with complete divulging of individual patient data of the original randomized controlled trials. We will remain with the
deﬁciencies of the original trials relating to the population studied, poor recording of clinically-signiﬁcant complications and the data that
were not kept. This experience should serve to improve the design of future trials, their documentation and preservation of patient data
for future analyses.
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E-mail: paulm@post.tau.ac.ilIn the midst of winter 2015, more than 15 years after the
marketing of neuraminidase inhibitors (NAIs) and after 46
placebo-controlled randomized controlled trials (RCTs) have
been conducted on oseltamivir and zanamivir, we remain un-
certain of their efﬁcacy [1]. In the current issue of the journal,
we invited three author groups to try and understand how it
came so and what should we do in clinical practice.
In a recent update of the Cochrane review on the efﬁcacy of
NAIs based on the clinical study reports for all RCTs, both
published and unpublished, the authors concluded strongly that
“Oseltamivir and zanamivir have small, non-speciﬁc effects on
reducing the time to alleviation of inﬂuenza symptoms in
adults” and that “Treatment trials with oseltamivir or zanamivir
do not settle the question of whether the complications of
inﬂuenza (such as pneumonia) are reduced” [2]. Indeed, the
presumed average 1-day beneﬁt of early NAIs administered
within 48 hours of symptom onset shrunk to 16.8 hours (95%
conﬁdence interval (CI) 8.4 to 25.1) in the complete analysis, a
statistically signiﬁcant beneﬁt, but doubtfully clinically
signiﬁcant.Microbiol Infect 2015; 21: 214–216
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.01.008The review included only placebo-controlled RCTs and used
clinical study reports rather than published data, even for those
studies that have been published. The authors stated that these
“were likely to provide the least biased, most complete and
most insightful set of data.” Quite astonishingly, 60% of the
patient data (3145 of 5267 patients randomized) were never
published. In the current issue, the review authors provide
explanations [3]. In response to critiques that the review
addressed only healthy adults, the authors clarify that the re-
view included all adult patients, including those with comor-
bidities that were included in the RCTs, except for patients
with primary immunodeﬁciency and cancer. Only two clinical
study reports addressed speciﬁcally patients with chronic lung
disease or elderly patients (each report compiling two or three
small RCTs), and effects in these trials do not seem different
than in the other trials. Thus, the data available for patients in
the community with comorbidities at risk for inﬂuenza com-
plications were scarce. Inﬂuenza complications were rare in
these trials and, in the Cochrane authors’ view, poorly re-
ported. For example, although a compilation of all recorded
pneumonia events showed that oseltamivir signiﬁcantly reduced
pneumonia (risk ratio 0.55, 95% CI 0.22 to 0.88, number
needed to treat of 100 patients), an analysis excluding pneu-
monias that were not well documented showed a smaller and
nonsigniﬁcant effect (relative risk 0.69, 95% CI 0.33 to 1.44).ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Editorial 215The Cochrane authors also concluded that “the inﬂuenza vi-
rus–speciﬁc mechanism of action proposed by the producers
does not ﬁt the clinical evidence.” Indeed, the beneﬁt in time to
symptom alleviation was similar for patients with and without
microbiological conﬁrmation of inﬂuenza in the RCTs assessing
zanamivir (the analysis could not be performed in the oselta-
mivir trials).
Nguyen-Van-Tam and colleagues [5] present two further
recent analyses. The ﬁrst is an individual patient data (IPD)
analysis of observational studies conducted during the 2009
H1N1 pandemic examining the associations between NAI
treatment and outcomes among hospitalized patients [6]. This
analysis showed a signiﬁcant association between NAI treat-
ment and lower mortality (adjusted odds ratio 0.81, 95% CI
0.70 to 0.93, 29 234 patients), with an even larger association
for early (within 48 hours) NAI administration (adjusted odds
ratio 0.50, 95% CI 0.37, 0.67, 16 425 patients). The authors
appropriately present the difﬁculties of drawing conclusions on
effects from observational data, especially when analysing the
competing effects of time to treatment on time to death. The
second is an IPD analysis of RCTs examining the efﬁcacy of
oseltamivir in the treatment of inﬂuenza in adults recently
published in The Lancet. [7]. Both IPD analyses were conducted
independently by the researchers, though funded by Roche.
Surprisingly, after a long struggle of the Cochrane authors to
obtain unpublished data, Roche supplied patient data for all of
its trials on oseltamivir. The IPD analysis included eight of the
nine RCTs on oseltamivir treatment analysed in the Cochrane
review and an additional RCT. The comparison of the aggregate
results of the Cochrane review and the IPD analysis is shown in
Table 1. Overall results are similar, with both analyses pointing
at the weaknesses of the deﬁnitions of pneumonia as anTABLE 1. Effect estimates for efﬁcacy measures in
randomized controlled trials on oseltamivir for the
treatment inﬂuenza in the intention to treat population of
the Cochrane review and the Lancet individual patient data
meta-analysis 1
Cochrane
(random effects model)
Lancet
(ﬁxed effect model)
Pneumonia
No RCTs 8 9
Risk ratio (95% CI) 0.55 (0.33 to 0.90) 0.34 (0.18 to 0.64)
Control event rate 2.22% 1.7%
NNT (95% CI) 100 (67 to 451) 154 (115–278)
Time to symptom alleviation
No RCTs 9 8
Effect estimate measured Mean difference Median difference
Difference in hours −16.76 (−25.10 to −8.42) −17.8 (−27.1 to −9.3)
Hospital admissions
No RCTs 7 8
Risk ratio (95% CI) 0.92 (0.57 to 1.50) 0.61 (0.36 to 1.03)
Control event rate 1.84% 1.84%
NNT (95% CI) 676 (not signiﬁcant) 139 (not signiﬁcant)
1RCTs – randomized controlled trials. NNT – number needed to treat
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyoutcome. Having individual patient data permitted more cor-
rect analysis of time to symptom alleviation using methods of
survival analysis and subgroup analyses. Separating patients with
documentation of inﬂuenza at baseline from those non-infected
showed larger effects among the infected and no effects in the
non-infected for all efﬁcacy outcomes. The beneﬁt in time to
symptom alleviation with oseltamivir was −25.2 hours among
infected patients (95% CI −36.2 to −16.0) with no difference
among the non-infected. Subgroup analysis of high-risk patients
(>65, with chronic comorbidities or chronic lung disease)
showed attenuated effects among them. Nausea and vomiting
were signiﬁcantly more common with oseltamivir compared to
placebo (risk ratios of 1.60, 95% CI 1.29 to 1.99 and 2.43, 1.83
to 3.23, respectively).
Finally, authors from Roche present their view [4]. A positive
outcome of the NAI conundrum was the intense debate on
unpublished data from RCTs that are not publicly available. The
Cochrane’s group struggle to obtain unpublished data resulted
in a data-sharing policy at Roche, a policy that we hope will be
shared by other companies. Among the difﬁculties in complying
with the Cochrane group’s request for trial data, Roche cites
patient privacy, noting that “the only type of data sharing
envisaged by the consent forms” was with regulatory author-
ities. Unpublished trials constitute a violation of patients’ con-
ﬁdence in the researcher who recruited them into the trial and
lower the public’s conﬁdence in medical research. Patients who
agree to participate in a trial do so in the belief and under-
standing that the trial will advance medical knowledge. There is
no violation of patients’ autonomy or privacy by sharing ano-
nymized data after the patient has agreed to participate in the
trial. Informed consent forms might have to be amended to
clarify the concept of data sharing.
What have we learned? RCTs show that in healthy people
NAIs have very little beneﬁt in the treatment of suspected or
conﬁrmed inﬂuenza. Complications were not well collected in
these trials and are indeed rare in healthy people. We lack
unbiased trial data for the patients at risk for inﬂuenza
complications: those in the community with comorbidities,
elderly people, and for those hospitalized due to inﬂuenza or
its complications. The best available observational data show a
possible advantage to NAIs in hospitalized patients. On this
shaky background comes the ﬁrst RCT testing a NAI among
inpatients [8]. This small trial, terminated early for futility,
compared peramivir (n = 78) to placebo (n = 43) in a
stratiﬁed subgroup of patients who did not receive NAIs as
part of the standard of care. There was no difference be-
tween study arms in time to clinical resolution (median 49.5
hours, 95% CI 40.0 to 61.9, with placebo vs. 42.5 hours, 95%
CI 34.0 to 57.9, p 0.97), complications or time to resumption
of usual activities. Mortality was low (2/121, 1.6%) comparedand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 214–216
216 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIto the 10% (2784/26 450) mortality observed in the obser-
vational studies [6], reﬂecting probably a less ill population
included in the RCT.
We summarize the evidence concluding that many trials
were conducted in the wrong population addressing the wrong
outcomes. Our conﬁdence in the observational studies is low,
yet the effect suggested deserves good research. A question
following the ﬁrst RCT of inpatients is whether this trial opens
the door for future RCTs testing antiviral therapies against
placebo among inpatients. Our answer is yes. Trials in the
relevant patient population with advanced methods for moni-
toring of outcomes throughout the trial should be conducted in
infectious diseases. The NAI story exempliﬁes much of the
evidence in infectious diseases accumulated for patients and for
indications different than those the drugs are used for in clinical
practice. With the NAI experience, we have gained better ac-
cess industry trial data but have yet to improve trial planning in
infectious diseases.Transparency declarationBoth authors report no conﬂicts of interest relevant to this
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